Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.36 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 2/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | TGM1 | P22735 | 1/20 | 0.33 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047203 | 0.88 | MEN1 (0.42) | BRD4CREBBPKDRNR1H2GPR119 | |
| SCHEMBL3047016 | 0.88 | PTPN2 (0.47) | GPR119MEN1KMT2A | |
| SCHEMBL3044227 | 0.85 | BRD4 (0.39) | BRD4CREBBPNR1H2ATRATRIP | |
| SCHEMBL3051536 | 0.85 | ALDH1A1 (0.45) | BRD4CREBBPNR1H2GPR119MEN1 | |
| SCHEMBL3034386 | 0.85 | BRD4 (0.51) | BRD4CREBBPNR1H2 | |
| SCHEMBL3043890 | 0.84 | BRD4 (0.38) | BRD4CREBBPNR1H2ATRATRIP | |
| SCHEMBL3047590 | 0.84 | NR1H2 (0.45) | BRD4CREBBPNR1H2ATRATRIP | |
| SCHEMBL3052592 | 0.83 | NR1H2 (0.36) | BRD4CREBBPNR1H2GPR119 | |
| SCHEMBL3046137 | 0.83 | PDCD1 (0.39) | BRD4CREBBPNR1H2 | |
| SCHEMBL3050173 | 0.83 | NR1H2 (0.37) | BRD4CREBBPNR1H2ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | BRD4 47/4885CREBBP 904/4885KDR 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.